Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 6, 2024

Insignis Therapeutics’ IN-001 clinical programme receives positive FDA response

Insignis Therapeutics has received a positive response from the US Food and Drug Administration (FDA) on IN-001 clinical programme for needle-free anaphylaxis treatment.

Continue
IN-001's proposed trials in healthy individuals could pave the way for FDA approval. Credit: National Cancer Institute on Unsplash.
November 5, 2024

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Through the deal, the parties also aim to create gene therapy R&D efforts in Singapore. Credit: Ring Therapeutics/GlobeNewswire.
November 4, 2024

NEOGAP and NorthX Biologics partner for cancer cell therapy production

NEOGAP Therapeutics is currently developing a cell therapy known as personalised tumour trained lymphocytes. Credit: NEOGAP Therapeutics.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Electra Therapeutics secures FDA ODD status for HLH treatment
  2. Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14
  3. FDA expands approval for Shorla’s JYLAMVO for paediatric patients
  4. Kivu Bioscience secures $92m in Series A funding for ADC development
  5. FDA grants IND clearance for RiboX’s RXRG001

PRESS RELEASES

BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer Remains on Track in First Half of 2024
Gerresheimer Remains on Track in First Half of 2024

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation